Chevy Chase Trust Holdings Inc. cut its holdings in shares of Agilent Technologies Inc (NYSE:A) by 0.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 273,013 shares of the medical research company’s stock after selling 2,187 shares during the period. Chevy Chase Trust Holdings Inc. owned about 0.09% of Agilent Technologies worth $16,883,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. boosted its position in Agilent Technologies by 10.8% in the 1st quarter. BlackRock Inc. now owns 28,445,160 shares of the medical research company’s stock valued at $1,902,983,000 after buying an additional 2,779,802 shares during the last quarter. OppenheimerFunds Inc. boosted its position in Agilent Technologies by 73.5% in the 1st quarter. OppenheimerFunds Inc. now owns 4,656,405 shares of the medical research company’s stock valued at $311,514,000 after buying an additional 1,973,089 shares during the last quarter. Old Mutual Global Investors UK Ltd. bought a new position in Agilent Technologies in the 1st quarter valued at $100,067,000. Royal Bank of Canada boosted its position in Agilent Technologies by 139.1% in the 1st quarter. Royal Bank of Canada now owns 404,795 shares of the medical research company’s stock valued at $27,080,000 after buying an additional 1,439,500 shares during the last quarter. Finally, Calamos Advisors LLC boosted its position in Agilent Technologies by 257.1% in the 2nd quarter. Calamos Advisors LLC now owns 936,713 shares of the medical research company’s stock valued at $57,926,000 after buying an additional 674,368 shares during the last quarter.
Several research firms have recently issued reports on A. Cowen upgraded Agilent Technologies from a “market perform” rating to an “outperform” rating in a research report on Tuesday, May 15th. Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, May 16th. Finally, ValuEngine lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 29th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $74.64.
Agilent Technologies opened at $66.69 on Friday, Marketbeat reports. Agilent Technologies Inc has a 12-month low of $58.22 and a 12-month high of $75.00. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.88 and a current ratio of 3.32. The firm has a market capitalization of $21.65 billion, a PE ratio of 26.33, a P/E/G ratio of 2.36 and a beta of 1.29.
Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, May 14th. The medical research company reported $0.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.01. Agilent Technologies had a return on equity of 18.01% and a net margin of 5.02%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same period last year, the company earned $0.58 EPS. The firm’s revenue was up 9.4% on a year-over-year basis. analysts forecast that Agilent Technologies Inc will post 2.67 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 25th. Investors of record on Tuesday, July 3rd were paid a dividend of $0.149 per share. This represents a $0.60 annualized dividend and a yield of 0.89%. The ex-dividend date was Monday, July 2nd. Agilent Technologies’s payout ratio is presently 25.42%.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.